Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David De Semir

Showing results (21-30 of 34) with videos related to

Pageof 4
Sort By:
The Journal of Investigative Dermatology|September 6, 2013
Prognostic impact of PHIP copy number in melanoma: linkage to ulcerationVladimir Bezrookove, David De Semir, Mehdi Nosrati, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 20, 2018
Role of Elevated <i>PHIP</i> Copy Number as a Prognostic and Progression Marker for Cutaneous MelanomaVladimir Bezrookove, Mehdi Nosrati, James R Miller, et al.
Cells|October 15, 2025
The GR-LEDGF/p75-HSP27 Axis Contributes to Cross-Resistance Between Enzalutamide and Docetaxel in Prostate CancerPedro T Ochoa, Evelyn S Sanchez-Hernandez, Alfonso M Duran, et al.
Cancer Research|March 26, 2021
Nuclear Receptor Coactivator NCOA3 Regulates UV Radiation-Induced DNA Damage and Melanoma SusceptibilityDavid de Semir, Vladimir Bezrookove, Mehdi Nosrati, et al.
Cancers|May 14, 2025
Inhibition of Mitochondrial-Associated Protein MAGMAS Resensitizes Chemoresistant Prostate Cancer Cells to DocetaxelAlfonso M Durán, Kristen Whitley, Krystal Santiago, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 6, 2018
PHIP as a therapeutic target for driver-negative subtypes of melanoma, breast, and lung cancerDavid de Semir, Vladimir Bezrookove, Mehdi Nosrati, et al.
Journal of the National Cancer Institute|February 26, 2015
The role of BPTF in melanoma progression and in response to BRAF-targeted therapyAltaf A Dar, Mehdi Nosrati, Vladimir Bezrookove, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 19, 2012
Pleckstrin homology domain-interacting protein (PHIP) as a marker and mediator of melanoma metastasisDavid De Semir, Mehdi Nosrati, Vladimir Bezrookove, et al.
The Journal of Clinical Investigation|July 10, 2025
Combinatorial therapy regimens targeting preclinical models of melanoma resistant to immune checkpoint blockadeImran Khan, Aida Rodriguez-Brotons, Anukana Bhattacharjee, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 11, 2020
PHIP drives glioblastoma motility and invasion by regulating the focal adhesion complexDavid de Semir, Vladimir Bezrookove, Mehdi Nosrati, et al.
Pageof 4

Showing results (21-30 of 34) with videos related to

Sort By:
Pageof 4
The Journal of Investigative Dermatology|September 6, 2013
Prognostic impact of PHIP copy number in melanoma: linkage to ulcerationVladimir Bezrookove, David De Semir, Mehdi Nosrati, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 20, 2018
Role of Elevated <i>PHIP</i> Copy Number as a Prognostic and Progression Marker for Cutaneous MelanomaVladimir Bezrookove, Mehdi Nosrati, James R Miller, et al.
Cells|October 15, 2025
The GR-LEDGF/p75-HSP27 Axis Contributes to Cross-Resistance Between Enzalutamide and Docetaxel in Prostate CancerPedro T Ochoa, Evelyn S Sanchez-Hernandez, Alfonso M Duran, et al.
Cancer Research|March 26, 2021
Nuclear Receptor Coactivator NCOA3 Regulates UV Radiation-Induced DNA Damage and Melanoma SusceptibilityDavid de Semir, Vladimir Bezrookove, Mehdi Nosrati, et al.
Cancers|May 14, 2025
Inhibition of Mitochondrial-Associated Protein MAGMAS Resensitizes Chemoresistant Prostate Cancer Cells to DocetaxelAlfonso M Durán, Kristen Whitley, Krystal Santiago, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 6, 2018
PHIP as a therapeutic target for driver-negative subtypes of melanoma, breast, and lung cancerDavid de Semir, Vladimir Bezrookove, Mehdi Nosrati, et al.
Journal of the National Cancer Institute|February 26, 2015
The role of BPTF in melanoma progression and in response to BRAF-targeted therapyAltaf A Dar, Mehdi Nosrati, Vladimir Bezrookove, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 19, 2012
Pleckstrin homology domain-interacting protein (PHIP) as a marker and mediator of melanoma metastasisDavid De Semir, Mehdi Nosrati, Vladimir Bezrookove, et al.
The Journal of Clinical Investigation|July 10, 2025
Combinatorial therapy regimens targeting preclinical models of melanoma resistant to immune checkpoint blockadeImran Khan, Aida Rodriguez-Brotons, Anukana Bhattacharjee, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 11, 2020
PHIP drives glioblastoma motility and invasion by regulating the focal adhesion complexDavid de Semir, Vladimir Bezrookove, Mehdi Nosrati, et al.
Pageof 4